BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12:1143-1152. [PMID: 30261763 DOI: 10.1080/17474124.2018.1530110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Ogawa M, Kanda T, Higuchi T, Takahashi H, Kaneko T, Matsumoto N, Nirei K, Yamagami H, Matsuoka S, Kuroda K, Moriyama M. Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease. Int J Med Sci 2019;16:909-21. [PMID: 31341404 DOI: 10.7150/ijms.34245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fan J, Shi Y, Peng Y. Autophagy and Liver Diseases. Adv Exp Med Biol 2020;1207:497-528. [PMID: 32671772 DOI: 10.1007/978-981-15-4272-5_37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lin E, Zou B, Zeng G, Cai C, Li P, Chen J, Li D, Zhang B, Li J. The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Ann Transl Med 2021;9:1310. [PMID: 34532447 DOI: 10.21037/atm-21-3731] [Reference Citation Analysis]
7 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis 2020;21:127-38. [PMID: 32108989 DOI: 10.1111/1751-2980.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. Int J Mol Sci 2020;21:E3308. [PMID: 32392802 DOI: 10.3390/ijms21093308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kiseleva YV, Zharikov YO, Maslennikov RV, Pavlov CS, Nikolenko VN. Molecular factors associated with regression of liver fibrosis of alcoholic etiology. Terapevticheskii arkhiv 2021;93:204-8. [DOI: 10.26442/00403660.2021.02.200617] [Reference Citation Analysis]
10 Liu Y, Wang C, Chen H, Zhang M, Zhu J, Zhang X, Ji L, Zhu S, Zhang W, Chen B. The profibrotic effects of chronic microaspiration of bile acids on lungs of rats at different stages. Int Immunopharmacol 2020;84:106545. [PMID: 32388214 DOI: 10.1016/j.intimp.2020.106545] [Reference Citation Analysis]
11 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
12 Weiskirchen R, Tacke F. Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease. Cells. 2019;8. [PMID: 30609663 DOI: 10.3390/cells8010016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
13 Zhou Z, Ren Q, Jiao S, Cai Z, Geng X, Deng L, Wang B, Hu L, Zhang L, Yang Y, Li Z. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. Eur J Med Chem 2021;229:114061. [PMID: 34954593 DOI: 10.1016/j.ejmech.2021.114061] [Reference Citation Analysis]
14 Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 2019;1:30-43. [PMID: 32149275 DOI: 10.1016/j.jhepr.2019.02.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 22.7] [Reference Citation Analysis]
15 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kataoka S, Umemura A, Okuda K, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Kanbara Y, Arbiser JL, Shima T, Okanoue T, Itoh Y. Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells. Int J Mol Sci 2021;22:13354. [PMID: 34948151 DOI: 10.3390/ijms222413354] [Reference Citation Analysis]
17 Zhang J, Wang W, Feng N, Jiang X, Zhu S, Chen YQ. Ndufa6 regulates adipogenic differentiation via Scd1. Adipocyte 2021;10:646-57. [PMID: 34793269 DOI: 10.1080/21623945.2021.2007590] [Reference Citation Analysis]
18 Wei F, Guo L, Xu Y, Chen D, Gong M. Comparative Pharmacokinetic Study of Taxifolin after Oral Administration of Fructus Polygoni Orientalis Extract in Normal and Fibrotic Rats by UPLC-MS/MS. Evid Based Complement Alternat Med 2019;2019:9348075. [PMID: 31976002 DOI: 10.1155/2019/9348075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Zhang X, Thompkins-Johns A, Ziober A, Zhang PJ, Furth EE. Hepatic Macrophage Types Cluster with Disease Etiology in Chronic Liver Disease and Differ Compared to Normal Liver: Implications for Their Biologic and Diagnostic Role. Int J Surg Pathol 2022;:10668969221099630. [PMID: 35521912 DOI: 10.1177/10668969221099630] [Reference Citation Analysis]
20 Silva CM, Ferrari GD, Alberici LC, Malaspina O, Moraes KCM. Cellular and molecular effects of silymarin on the transdifferentiation processes of LX-2 cells and its connection with lipid metabolism. Mol Cell Biochem 2020;468:129-42. [PMID: 32185674 DOI: 10.1007/s11010-020-03717-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, Irving W, Forrest E, Pedergnana V, Goldberg D, Aspinall E, Barclay S, Hayes PC, Dillon J, Nischalke HD, Lutz P, Spengler U, Fischer J, Berg T, Brosch M, Eyer F, Datz C, Mueller S, Peccerella T, Deltenre P, Marot A, Soyka M, McQuillin A, Morgan MY, Hampe J, Stickel F. Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology 2020;159:1276-1289.e7. [PMID: 32561361 DOI: 10.1053/j.gastro.2020.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
22 Gual P. Pharmacological treatments of the "Fibrotic-NASH": Towards a delivery on time? Clin Res Hepatol Gastroenterol 2019;43:623-4. [PMID: 31300372 DOI: 10.1016/j.clinre.2019.06.013] [Reference Citation Analysis]
23 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Reference Citation Analysis]
24 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
25 Liu X, Wang D, Yang W, Wu X. Oxymatrine exerts anti-fibrotic effects in a rat model of hepatic fibrosis by suppressing endoplasmic reticulum stress. J Int Med Res 2020;48:300060520961681. [PMID: 33044865 DOI: 10.1177/0300060520961681] [Reference Citation Analysis]
26 Chilvery S, Bansod S, Saifi MA, Godugu C. Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways. Int Immunopharmacol 2020;88:106909. [PMID: 32882664 DOI: 10.1016/j.intimp.2020.106909] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 Li Z, Zhou Z, Hu L, Deng L, Ren Q, Zhang L. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacol Res 2020;159:105035. [PMID: 32562818 DOI: 10.1016/j.phrs.2020.105035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Salvati A, Poelstra K. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation. Pharmaceutics 2022;14:217. [DOI: 10.3390/pharmaceutics14010217] [Reference Citation Analysis]
29 Mannaerts I, Eysackers N, Anne van Os E, Verhulst S, Roosens T, Smout A, Hierlemann A, Frey O, Leite SB, van Grunsven LA. The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation. Biomaterials 2020;261:120335. [PMID: 32891040 DOI: 10.1016/j.biomaterials.2020.120335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Cheng QC, Fan J, Deng XW, Liu HC, Ding HR, Fang X, Wang JW, Chen CH, Zhang WG. Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis. World J Gastroenterol 2020; 26(41): 6346-6360 [PMID: 33244197 DOI: 10.3748/wjg.v26.i41.6346] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Reference Citation Analysis]
32 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Reference Citation Analysis]
33 Poelstra K. Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Curr Tissue Microenviron Rep 2020;1:13-22. [DOI: 10.1007/s43152-020-00004-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li J, Liu C, Zhou Z, Dou B, Huang J, Huang L, Zheng P, Fan S, Huang C. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. Phytother Res 2021;35:3351-64. [PMID: 33784797 DOI: 10.1002/ptr.7055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Kuang M, Wu H, Hu L, Guo X, He D, Liu B, Chen M, Gu J, Gu J, Zeng X, Ruan Y. Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis. Glycoconj J 2021;38:77-87. [PMID: 33608773 DOI: 10.1007/s10719-021-09975-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
37 Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med 2020;20:289-97. [PMID: 32078718 DOI: 10.1007/s10238-020-00617-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Puengel T, De Vos S, Hundertmark J, Kohlhepp M, Guldiken N, Pujuguet P, Auberval M, Marsais F, Shoji KF, Saniere L, Trautwein C, Luedde T, Strnad P, Brys R, Clément-Lacroix P, Tacke F. The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. J Clin Med 2020;9:E1140. [PMID: 32316235 DOI: 10.3390/jcm9041140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
39 Pinheiro D, Dias I, Ribeiro Silva K, Stumbo AC, Thole A, Cortez E, de Carvalho L, Weiskirchen R, Carvalho S. Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview. Cells 2019;8:E1339. [PMID: 31671842 DOI: 10.3390/cells8111339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]